[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 63 of about 63
1. Tanaka K, Sasayama T, Kawamura A, Kondoh T, Kanomata N, Kohmura E: Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion. Neurol Med Chir (Tokyo); 2006 Apr;46(4):198-201
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated oculomotor nerve paresis in anaplastic astrocytoma with exophytic invasion.
  • Computed tomography and magnetic resonance imaging showed an intra-axial tumor in the left temporal lobe, extending to the basal and prepontine cisterns, and compressing the brainstem.
  • The histological diagnosis was anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / complications. Oculomotor Nerve Diseases / etiology. Supratentorial Neoplasms / complications. Temporal Lobe
  • [MeSH-minor] Adult. Astrocytes / pathology. Biomarkers, Tumor / analysis. Brain Stem / pathology. Cerebral Arteries / pathology. Cisterna Magna / pathology. Dominance, Cerebral / physiology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Nerve Compression Syndromes / diagnosis. Nerve Compression Syndromes / etiology. Nerve Compression Syndromes / pathology. Nerve Compression Syndromes / surgery. Neuronavigation. Oculomotor Nerve / pathology. Oculomotor Nerve / surgery. Pons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636512.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Gupta B, Raina J: Fascicular multiple ocular motor nerve paresis as first presentation of anaplastic astrocytoma. Indian J Ophthalmol; 2007 Nov-Dec;55(6):458-60
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascicular multiple ocular motor nerve paresis as first presentation of anaplastic astrocytoma.
  • A case of spontaneous, painless partial III (pupil-sparing) and IV fascicular nerve paresis as the first presentation of anaplastic astrocytoma is reported.
  • [MeSH-major] Astrocytoma / complications. Brain Stem Neoplasms / complications. Oculomotor Nerve Diseases / etiology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Eye Movements. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiologe. 1999 Oct;39(10):821-7 [10550380.001]
  • [Cites] Acta Neurochir (Wien). 1979;49(1-2):35-45 [230705.001]
  • [Cites] J Clin Neurosci. 2005 Nov;12(8):946-9 [16326274.001]
  • [Cites] Neurol Neurochir Pol. 1983 Jul-Aug;17(4):471-5 [6646330.001]
  • [Cites] Neurosurgery. 1982 Apr;10(4):437-44 [7099393.001]
  • (PMID = 17951905.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2635986
  •  go-up   go-down


3. Hafez RF: Stereotaxic gamma knife surgery in treatment of critically located pilocytic astrocytoma: preliminary result. World J Surg Oncol; 2007;5:39
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotaxic gamma knife surgery in treatment of critically located pilocytic astrocytoma: preliminary result.
  • BACKGROUND: Low-grade gliomas are uncommon primary brain tumors, located more often in the posterior fossa, optic pathway, and brain stem and less commonly in the cerebral hemispheres.
  • CASE PRESENTATIONS: Two patients with diagnosed recurrent cystic pilocytic astrocytoma critically located within the brain (thalamic and brain stem) were treated with gamma knife surgery.
  • Progressive reduction on the magnetic resonance imaging (MRI) studies of the solid part of the tumor and almost disappearance of the cystic component was achieved within the follow-up period of 36 months in the first case with the (thalamic located lesion) and 22 months in the second case with the (brain stem located lesion).
  • CONCLUSION: Gamma knife surgery represents an alternate tool in the treatment of recurrent and/or small postoperative residual pilocytic astrocytoma especially if they are critically located.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Adult. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Child. Female. Humans. Magnetic Resonance Imaging. Thalamic Diseases / pathology. Thalamic Diseases / surgery. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):43-51 [12007940.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):677-80 [12507119.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1132-9; discussion [16331161.001]
  • [Cites] Neurochirurgie. 1998 Mar;44(1):50-4 [9757318.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:19-24 [15662774.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):374-9 [15667955.001]
  • [Cites] Acta Neurochir Suppl. 2004;91:89-102 [15707030.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):696-701; discussion 701-2 [8692387.001]
  • (PMID = 17394660.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1852107
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


Advertisement
4. Oka F, Yamashita Y, Kumabe T, Tominaga T: Total resection of a hemorrhagic tectal pilocytic astrocytoma--case report. Neurol Med Chir (Tokyo); 2007 May;47(5):219-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total resection of a hemorrhagic tectal pilocytic astrocytoma--case report.
  • A 21-year-old man presented with a hemorrhagic pilocytic astrocytoma of the tectal plate manifesting as sudden onset of severe headache, vertigo, nausea, and vomiting.
  • Computed tomography demonstrated acute hydrocephalus and hemorrhage within the brain stem and fourth ventricle.
  • The histological diagnosis was pilocytic astrocytoma.
  • Tectal plate pilocytic astrocytoma is rarely associated with hemorrhage but should be considered in the differential diagnosis of intracranial hemorrhage with acute presentation.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Intracranial Hemorrhages / etiology. Tectum Mesencephali
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527049.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Kumar AJ, Leeds NE, Kumar VA, Fuller GN, Lang FF, Milas Z, Weinberg JS, Ater JL, Sawaya R: Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas. J Comput Assist Tomogr; 2010 Jul;34(4):601-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas.
  • OBJECTIVE: The typical magnetic resonance/computed tomographic imaging appearance of pilocytic astrocytoma (PA) is that of a cyst with an intensely enhancing mural nodule.
  • METHODS: One hundred patients referred to the cancer center with brain tumors histologically proven to be PA were retrospectively reviewed (95 by magnetic resonance imaging and 5 by computed tomographic imaging) and analyzed.
  • Tumor locations consisted of the following: optic chiasm (22), lateral ventricle (3), thalamus (12), basal ganglia (1), cerebral hemisphere (10), corpus callosum (2), brain stem (26), fourth ventricle (1), and cerebellum (23).
  • CONCLUSIONS: It is important to recognize the aggressive imaging appearance of PA (grade 1 astrocytoma) because it can be mistaken for high-grade gliomas and may thus lead to inappropriate therapy.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Brain / pathology. Brain / radiography. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed / methods. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657231.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Tanaka S, Kobayashi I, Utsuki S, Iwamoto K, Takanashi J: Biopsy of brain stem glioma using motor-evoked potential mapping by direct peduncular stimulation and individual adjuvant therapy. Case report. Neurol Med Chir (Tokyo); 2005 Jan;45(1):49-55
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biopsy of brain stem glioma using motor-evoked potential mapping by direct peduncular stimulation and individual adjuvant therapy. Case report.
  • A 23-year-old man presented with a brain stem glioma manifesting as a 6-month history of right hemiparesis and diplopia.
  • Serial magnetic resonance imaging showed an intrinsic diffuse brain stem glioma that gradually localized to the left cerebral peduncle after initial adjuvant therapy.
  • The histological diagnosis was anaplastic astrocytoma.
  • Surgery under pyramidal tract mapping and intensive postoperative adjuvant therapy resulted in a good outcome despite the presence of a generally intractable intrinsic brain stem glioma.
  • [MeSH-major] Astrocytoma / surgery. Brain Mapping. Brain Stem Neoplasms / surgery. Evoked Potentials, Motor. Mesencephalon / physiopathology. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Biopsy / methods. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699622.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Muthukrishnan A, Bajoghli M, Mountz JM: Delayed development of radiation vasculopathy of the brain stem confirmed by F-18 FDG PET in a case of anaplastic astrocytoma. Clin Nucl Med; 2007 Jul;32(7):527-31
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed development of radiation vasculopathy of the brain stem confirmed by F-18 FDG PET in a case of anaplastic astrocytoma.
  • We present the imaging findings of a 38-year-old female patient who underwent resection and radiation therapy for an anaplastic astrocytoma in her left temporal lobe 12 years ago.
  • Magnetic resonance imaging (MRI) of the brain showed a new mass lesion in the left pontine region of the brain stem.
  • Therefore, an F-18 FDG brain PET scan was performed, which demonstrated no metabolic activity in the pontine lesion leading to the less common diagnosis of long-term postradiation vasculopathy.
  • This case illustrates the importance of considering the rare diagnosis of radiation-induced vasculopathy in the differential diagnosis when symptoms of recurrent brain tumor occur.
  • [MeSH-major] Brain Stem / radionuclide imaging. Cerebrovascular Disorders / etiology. Cerebrovascular Disorders / radionuclide imaging. Fluorodeoxyglucose F18. Radiation Injuries / etiology. Radiation Injuries / radionuclide imaging. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Astrocytoma / radionuclide imaging. Astrocytoma / radiotherapy. Female. Humans. Positron-Emission Tomography / methods. Radiopharmaceuticals. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581336.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Bayrakli F, Dinçer A, Sav A, Vardareli E, Peker S: Late brain stem radionecrosis seventeen years after fractionated radiotherapy. Turk Neurosurg; 2009 Apr;19(2):182-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late brain stem radionecrosis seventeen years after fractionated radiotherapy.
  • The appearance of a new lesion several years after radiation treatment for a primary brain tumor may represent different kind of pathologies.
  • We present a 24-year-old patient who suffered from right-sided hemiparesis and ataxic gait with a history of an operation due to left frontoparieal grade II fibrillary astrocytoma and fractioned radiotherapy.
  • His cranial MRI study showed heterogeneous signal intensity of brain stem radionecrosis in the pons spreading through the mesencephalon and left brachium pontis.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Brain Stem / pathology. Radiation Injuries / pathology
  • [MeSH-minor] Biopsy. Humans. Magnetic Resonance Imaging. Male. Necrosis. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19431132.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


9. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, Shao N, Qu H, Yang C, Zhang Y, Wang Q, Wang R, Zen K, Zhang CY, Zhang J, Yang Y: The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer; 2010 Jun;46(9):1640-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.
  • In the present study, the miRNA expression profile was examined in astrocytoma, a malignant and prevalent intracranial tumour in adults.
  • METHODS: We screened the expression profile of 200 miRNAs in a training sample set consisting of 84 astrocytoma samples and 20 normal adjacent tissue (NAT) samples using the method of stem-loop quantitative RT-PCR.
  • The significantly altered miRNAs were validated in another independent sample set consisting of 40 astrocytoma samples and 40 NAT samples.
  • The correlation of the miRNA levels with survival in astrocytoma samples was estimated by performing Kaplan-Meier survival analysis and univariate/multivariate Cox proportional hazard regression analysis.
  • RESULTS: After a two-phase selection and validation process, seven miRNAs were found to have a significantly different expression profile in astrocytoma samples upon comparison to the NAT samples.
  • Unsupervised clustering analysis further revealed the great potential of the 7-miRNA profile to differentiate between tumours and normal brain tissues.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. MicroRNAs / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Protein Array Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219352.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN106 microRNA, human; 0 / MIRN21 microRNA, human; 0 / MIrn181 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


10. Berhouma M, Jemel H, Kchir N: Calcified pilocytic astrocytoma of the medulla mimicking a brainstem "stone". Pathologica; 2008 Oct;100(5):408-10
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcified pilocytic astrocytoma of the medulla mimicking a brainstem "stone".
  • Brainstem gliomas are a heterogeneous group of tumours commonly found in children, comprising about 10% of central nervous system tumours in paediatric patients, but less than 2% in adults.
  • Thin calcifications can be normally found within low grade gliomas, but densely calcified pilocytic astrocytomas of the brainstem have been only rarely reported.
  • We present the case of a young man presenting with a large brainstem calcification involving the medulla, which was subtotally resected using a posterior suboccipital approach.
  • The definitive pathological diagnosis was calcified pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Stem Neoplasms / diagnosis. Calcinosis / diagnosis. Medulla Oblongata / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Gait Ataxia / etiology. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253601.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Francesco F, Maurizio I, Stefano C, Marina S, Ugo S, Massimo S: Trigeminal nerve root entry zone pilocytic astrocytoma in an adult: a rare case of an extraparenchymal tumor. J Neurooncol; 2010 Apr;97(2):285-90
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trigeminal nerve root entry zone pilocytic astrocytoma in an adult: a rare case of an extraparenchymal tumor.
  • Extra-axial cerebellopontine angle (CPA) tumors account for approximately 10% of all brain neoplasms in adults.
  • Gliomas in the CPA are rare and quite often are the exophytic extension of primary brain stem or cerebellar tumors.
  • We describe a pilocytic astrocytoma of the CPA that was found to arise from the proximal portion of trigeminal nerve without any anatomic continuity with the brain stem and the cerebellum.
  • [MeSH-major] Astrocytoma / pathology. Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology. Cranial Nerve Neoplasms / pathology. Trigeminal Nerve Diseases / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1980 Aug;106(8):456-9 [7396789.001]
  • [Cites] J Laryngol Otol. 1980 Dec;94(12):1353-62 [7441048.001]
  • [Cites] Surg Neurol. 2008 Jul;70(1):87-91 [18313733.001]
  • [Cites] J Neuropathol Exp Neurol. 1948 Oct;7(4):349-67 [18889208.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):859-63 [8487066.001]
  • [Cites] J Neurooncol. 2000 Sep;49(3):205-12 [11212899.001]
  • [Cites] Eur Radiol. 2004 Jul;14(7):1169-73 [14740164.001]
  • [Cites] Neuroradiology. 1993;35(4):274-8 [8492893.001]
  • [Cites] Bull Johns Hopkins Hosp. 1948 Sep;83(3):187-212 [18877371.001]
  • [Cites] Neurosurgery. 2006 Oct;59(4):E939-40; discussion E940 [17038929.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):125-8 [8587672.001]
  • [Cites] Childs Nerv Syst. 2009 Feb;25(2):247-51 [18690462.001]
  • [Cites] Am J Otolaryngol. 1980 Feb;1(2):141-6 [7446836.001]
  • (PMID = 19820900.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Wang CC, Zhang JT, Liu AL: [Surgical management of brain-stem gliomas: a retrospective analysis of 311 cases]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb;27(1):7-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical management of brain-stem gliomas: a retrospective analysis of 311 cases].
  • OBJECTIVE: To further study the clinical features, diagnosis, and surgery outcome of brain-stem gliomas.
  • METHODS: Totally 311 patients with brain-stem gliomas received surgery operations in our hospital from 1980 to the end of 2001.
  • RESULTS: Different brain-stem gliomas showed different growth patterns.
  • Five years survival rate is 67% in ependymoma patients, 42% in astrocytoma patients.
  • None of brain-stem glioblastoma patients survived up to 5 years.
  • CONCLUSIONS: The histology and growth pattern of brainstem gliomas varies.
  • The patients with well-differentiated gliomas of brain-stem may be cured by microsurgical removal.
  • [MeSH-major] Astrocytoma / surgery. Brain Stem Neoplasms / surgery. Ependymoma / surgery. Glioblastoma / surgery. Neurosurgical Procedures
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Mesencephalon / surgery. Microsurgery / methods. Middle Aged. Pons / surgery. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782484.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Malakootian M, Mowla SJ, Saberi H, Asadi MH, Atlasi Y, Shafaroudi AM: Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors. Mol Carcinog; 2010 Sep;49(9):818-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors.
  • Nucleostemin (NS) is implicated in the control of stem and cancer cell proliferation.
  • In the present study, we have examined the expression of NS and its spliced variants in various brain tumors.
  • Total RNA was extracted from 59 brain tumor samples, and the expression of different NS spliced variants was measured by semi-quantitative RT-PCR.
  • The subcellular distribution of NS protein in brain tumors was further examined by immunohistochemistry.
  • Furthermore, to decipher the potential involvement of NS in brain tumorogenesis, its expression was knocked-down by means of RNA interference (RNAi) in two malignant glioma (U-87MG and A172), one astrocytoma (1321N1) and one medulloblastoma (DAOY) cell lines.
  • Our data revealed that NS and its variants are widely expressed in different types of brain tumors.
  • All in all, our data suggest a potential role for NS in tumorogenesis of brain cancers.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Glioma / metabolism
  • [MeSH-minor] Adult. Brain / metabolism. Cell Cycle / genetics. Cell Line. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Medulloblastoma / genetics. Medulloblastoma / metabolism. Medulloblastoma / pathology. Middle Aged. Proteins / genetics. Proteins / metabolism. RNA Interference. RNA Splicing. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Stem Cells / metabolism. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20572164.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; 0 / RNA, Small Interfering
  •  go-up   go-down


14. Park HJ, Kim JK, Jeon HM, Oh SY, Kim SH, Nam DH, Kim H: The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells. Mol Cells; 2010 Nov;30(5):403-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells.
  • A growing body of evidence indicates that deregulation of stem cell fate determinants is a hallmark of many types of malignancies.
  • The neural stem cell fate determinant TLX plays a pivotal role in neurogenesis in the adult brain by maintaining neural stem cells.
  • Here, we report a tumorigenic role of TLX in brain tumor initiation and progression.
  • Increased TLX expression was observed in a number of glioma cells and glioma stem cells, and correlated with poor survival of patients with gliomas.
  • Furthermore, overexpression of TLX in Ink4a/Arf(-/-) astrocytes inhibited cell migration and invasion and promoted neurosphere formation and Nestin expression, which are hallmark characteristics of glioma stem cells, under stem cell culture conditions.
  • Our results indicate that TLX is involved in glioma stem cell genesis and represents a potential therapeutic target for this type of malignancy.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioma / pathology. Neoplastic Stem Cells / pathology. Neural Stem Cells / pathology. Receptors, Cytoplasmic and Nuclear / physiology
  • [MeSH-minor] Adult. Animals. Astrocytes / metabolism. Astrocytes / pathology. Astrocytoma / genetics. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Central Nervous System Neoplasms. Cyclin D / genetics. Humans. Intermediate Filament Proteins / genetics. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Metastasis. Nerve Tissue Proteins / genetics. Nestin. Neurogenesis. Prognosis. Up-Regulation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mol Cells. 2011 Feb ;31(2):199. Park, Myung-Jin [removed]; Soeda, Akio [removed]
  • (PMID = 20814749.001).
  • [ISSN] 0219-1032
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / NR2E1 protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Receptors, Cytoplasmic and Nuclear
  •  go-up   go-down


15. Foreman NK, Schissel D, Le T, Strain J, Fleitz J, Quinones R, Giller R: A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J Neurooncol; 2005 Jan;71(2):181-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors.
  • PURPOSE: To determine the maximum tolerated dose (MTD) of carboplatin with autologous hematopoietic stem-cell rescue, in children with poor-prognosis brain tumors.
  • PATIENTS AND METHODS: A previously determined dose of cyclophosphamide with stem-cell rescue was used as a first course.
  • In a second course, carboplatin was given for 3 days with stem-cell rescue to 20 children.
  • One child with a metastatic anaplastic astrocytoma had a CR.
  • CONCLUSION: The MTD of carboplatin with stem-cell rescue is 700 mg/m2/day for 3 days.
  • Sequential stem-cell supported cyclophosphamide and carboplatin was tolerable in children with brain tumors and produced responses in PNETs and Germinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Drug Resistance, Neoplasm. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Jan 15;57(2):222-5 [3510700.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Fall;12(3):297-300 [2173440.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):572-82 [2319316.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):67-73 [9525840.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Bone Marrow Transplant. 1992 Nov;10 (5):457-62 [1464010.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1693-7 [6367971.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1814-23 [9164190.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):153-60 [10918425.001]
  • [Cites] Oncologist. 1996;1(6):381-393 [10388020.001]
  • [Cites] Cancer Chemother Pharmacol. 1982;9(3):140-7 [6761010.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):787-94 [12942106.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):227-33 [1534708.001]
  • [Cites] Cancer Treat Rep. 1984 Sep;68(9):1103-14 [6383605.001]
  • [Cites] J Clin Oncol. 1989 May;7(5):651-61 [2651580.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2426-34 [9667260.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2127-36 [10561268.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1056-68 [8584145.001]
  • [Cites] J Clin Oncol. 1989 Jun;7(6):754-60 [2715805.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1581-91 [12697884.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):520-8 [1548516.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3183-5 [12860965.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5432-8 [6386150.001]
  • [Cites] Cancer Res. 1983 Sep;43(9):4470-3 [6347373.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):69-74 [8817417.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3258-65 [9336363.001]
  • (PMID = 15690136.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


16. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, Held-Feindt J: Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol; 2008 Jan;86(1):31-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of stem cell markers in human astrocytomas of different WHO grades.
  • According to new hypotheses astrocytomas/gliomas either arise from or attract neural stem cells.
  • Biological markers, particularly antigenic markers, have played a significant role for the characterization of these tumour stem cells (TSCc).
  • Because these studies have been performed with single experimental samples mostly from gliomas, we investigated the expression of the stem cell markers CD133/Prominin, Nestin, Sox-2, Musashi-1, CXCR4, Flt-4/VEGFR-3 and CD105/Endoglin in 72 astrocytomas of different WHO-grades and compared it to normal adult human brain.
  • In contrast to normal brain, tumour samples showed a high variability for the expression of all markers.
  • Our results show that most astrocytomas contain considerable portions of cells expressing stem cell markers.
  • It appears that some of these cells originate from tumour genesis (supporting the stem cell hypothesis) while others are attracted by the tumours.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gene Expression / physiology. Nerve Tissue Proteins / metabolism. Stem Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Child. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):150-4 [12054577.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):303-13 [1538585.001]
  • [Cites] Genes Dev. 2003 Jan 1;17(1):126-40 [12514105.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2012-21 [10979941.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):198-204 [12869303.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5551-8 [12359767.001]
  • [Cites] Glia. 2001 Apr 1;34(1):1-7 [11284014.001]
  • [Cites] Brain Res. 1999 Aug 14;838(1-2):1-10 [10446310.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] Glia. 2006 Dec;54(8):850-60 [16981197.001]
  • [Cites] Blood. 2003 Jan 1;101(1):168-72 [12393704.001]
  • [Cites] Histopathology. 2005 Oct;47(4):348-56 [16178889.001]
  • [Cites] Immunity. 2003 Oct;19(4):525-33 [14563317.001]
  • [Cites] J Comp Neurol. 2004 Feb 9;469(3):311-24 [14730584.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Glia. 1995 Nov;15(3):211-21 [8586458.001]
  • [Cites] Aging Cell. 2005 Aug;4(4):197-207 [16026334.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):124-37 [11550308.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):1-8 [16078101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):826-36 [2585073.001]
  • [Cites] Neurosci Lett. 2005 Jul 1-8;382(1-2):88-92 [15911127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15468-73 [12438646.001]
  • [Cites] Neurobiol Dis. 1995 Apr;2(2):79-85 [8980011.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23 ):10946-51 [16322242.001]
  • [Cites] J Neurosci. 1985 Dec;5(12):3310-28 [4078630.001]
  • [Cites] Mol Vis. 2005 Sep 12;11:729-37 [16179903.001]
  • [Cites] Int J Dev Neurosci. 2002 Feb;20(1):29-38 [12008072.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Nature. 1990 Oct 25;347(6295):762-5 [2172829.001]
  • [Cites] J Neurosci. 1997 Nov 1;17(21):8300-12 [9334405.001]
  • [Cites] J Mol Neurosci. 2005;27(2):167-74 [16186627.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Gene Expr Patterns. 2007 Aug;7(7):817-25 [17544341.001]
  • [Cites] Lab Invest. 1995 Aug;73(2):213-20 [7637321.001]
  • [Cites] Nat Neurosci. 2006 Mar;9(3):340-8 [16462734.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Dev Biol. 1996 Jun 15;176(2):230-42 [8660864.001]
  • [Cites] Eur J Neurosci. 1997 Jan;9(1):65-75 [9042570.001]
  • [Cites] Leuk Lymphoma. 2001 Nov-Dec;42(6):1195-206 [11911400.001]
  • [Cites] Neuroscience. 2002;115(1):295-305 [12401342.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3566-70 [7724599.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23 ):12425-30 [9356465.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2635-45 [7590241.001]
  • [Cites] FASEB J. 2005 Nov;19(13):1860-2 [16150803.001]
  • [Cites] Mol Cell Neurosci. 2001 Feb;17(2):259-73 [11178865.001]
  • [Cites] J Biol Chem. 1992 Sep 25;267(27):19027-30 [1326540.001]
  • [Cites] Cell. 1999 Jan 8;96(1):25-34 [9989494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Differentiation. 2001 Sep;68(2-3):141-52 [11686236.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Glia. 1995 Nov;15(3):328-38 [8586467.001]
  • [Cites] EMBO J. 1993 Oct;12(10):3847-54 [8404853.001]
  • (PMID = 17611714.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Nerve Tissue Proteins
  •  go-up   go-down


17. Tchoghandjian A, Fernandez C, Colin C, El Ayachi I, Voutsinos-Porche B, Fina F, Scavarda D, Piercecchi-Marti MD, Intagliata D, Ouafik L, Fraslon-Vanhulle C, Figarella-Branger D: Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature. Brain; 2009 Jun;132(Pt 6):1523-35
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature.
  • [MeSH-major] Astrocytoma / diagnosis. Optic Nerve Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Astrocytes / metabolism. Cell Proliferation. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / genetics. Cerebellar Neoplasms / pathology. Child. Child, Preschool. DNA, Neoplasm / genetics. Diagnosis, Differential. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Hypothalamus / metabolism. Infant. Middle Aged. Neoplastic Stem Cells / pathology. Neuroglia / pathology. Oligonucleotide Array Sequence Analysis / methods. Optic Chiasm / cytology. Optic Chiasm / embryology. Optic Chiasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Up-Regulation. Vimentin / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336457.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Vimentin
  •  go-up   go-down


18. Mao Y, Zhou L, Zhu W, Wang X, Yang G, Xie L, Mao X, Jin K: Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas. Front Biosci; 2007;12:2252-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas.
  • Tumor stem cells are implicated in tumor initiation and maintenance.
  • Recent studies have shown that a subpopulation of cells isolated from brain tumors can form neurospheres in vitro, and have multiple characteristic properties observed in neural stem cells.
  • In vivo implantation of these cells can induce tumors that phenocopy original tumors, suggesting that tumor stem cells are involved in brain carcinogenesis.
  • We found that a population of cells in human glioblastoma multiforme expressed multiple protein markers of neural stem cells including nestin, TUC-4, doublecortin and beta III-tubulin.
  • To investigate further whether these properties of tumor stem cells are correlated with their biological behavior, immunohistochemistry was performed on brain sections from astrocytomas of different grades using antibodies against neural stem cell markers.
  • The number of cells expressing Ki67 antigen and neural stem cell markers was increased in relation to worsening histological grade of astrocytomas, indicating that the capacity for tumor stem cell proliferation may be clinically relevant.
  • Thus, tumor stem cells in astrocytomas may be involved in carcinogenesis.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Middle Aged. Neurons / metabolism. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127461.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG21980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


19. MacDonald TJ, Arenson EB, Ater J, Sposto R, Bevan HE, Bruner J, Deutsch M, Kurczynski E, Luerssen T, McGuire-Cullen P, O'Brien R, Shah N, Steinbok P, Strain J, Thomson J, Holmes E, Vezina G, Yates A, Phillips P, Packer R: Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer; 2005 Dec 15;104(12):2862-71
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933.
  • BACKGROUND: High-grade astrocytomas (HGA) carry a dismal prognosis and compose nearly 20% of all childhood brain tumors.
  • [MeSH-minor] Adolescent. Adult. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / mortality. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / radiotherapy. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Neoplasm Staging. Probability. Prognosis. Prospective Studies. Radiotherapy, High-Energy. Reference Values. Risk Assessment. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16315242.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


20. Dasgupta B, Gutmann DH: Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci; 2005 Jun 8;25(23):5584-94
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo.
  • Neurofibromatosis 1 (NF1) is a common inherited disease in which affected children exhibit abnormalities in astrocyte growth regulation and are prone to the development of brain tumors (astrocytoma).
  • Here, we directly examined the consequences of Nf1 inactivation on neural stem cell (NSC) proliferation in vitro and in vivo.
  • Finally, the increase in astroglial progenitors and proliferating cells seen in vitro was also observed in Nf1-/- and Nf1+/- embryonic as well as Nf1+/- adult brains in vivo.
  • Collectively, these findings support the hypothesis that alterations in neurofibromin expression in the developing brain have significant consequences for astrocyte growth and differentiation relevant to normal brain development and astrocytoma formation in children.
  • [MeSH-major] Astrocytes / physiology. Neurofibromin 1 / physiology. Stem Cells / physiology
  • [MeSH-minor] Animals. Brain / cytology. Cell Differentiation. Cell Proliferation. Cell Survival. Cells, Cultured. Embryo, Mammalian / cytology. Male. Mice. Mice, Mutant Strains. Multipotent Stem Cells / physiology. Transplantation, Heterologous


21. Sandri A, Sardi N, Genitori L, Giordano F, Peretta P, Basso ME, Bertin D, Mastrodicasa L, Todisco L, Mussa F, Forni M, Ricardi U, Cordero di Montezemolo L, Madon E: Diffuse and focal brain stem tumors in childhood: prognostic factors and surgical outcome. Experience in a single institution. Childs Nerv Syst; 2006 Sep;22(9):1127-35
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse and focal brain stem tumors in childhood: prognostic factors and surgical outcome. Experience in a single institution.
  • OBJECTIVE: Brainstem tumors (BSTs) are usually gliomas and are divided into diffuse BSTs (DBSTs) and focal BSTs (FBSTs).
  • [MeSH-major] Astrocytoma / surgery. Brain Stem Neoplasms / surgery. Ganglioglioma / surgery
  • [MeSH-minor] Adolescent. Adult. Brain Stem / pathology. Brain Stem / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Prognosis. Radiation-Sensitizing Agents / administration & dosage. Radiotherapy, Adjuvant. Survival Rate. Vincristine / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 1994;20(1):2-10 [8142279.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):239-48 [1964962.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30 [8133987.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1991;53:148-58 [1803873.001]
  • [Cites] Med Pediatr Oncol. 1989;17(2):117-26 [2704333.001]
  • [Cites] J Neurosurg. 1987 Feb;66(2):227-33 [3806204.001]
  • [Cites] Neurosurgery. 1992 Aug;31(2):186-94 [1308661.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):751-5 [3772472.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):483-90 [9835900.001]
  • [Cites] Pediatr Neurosurg. 2001 Apr;34(4):206-14 [11359114.001]
  • [Cites] J Neurooncol. 1989 Nov;7(4):367-71 [2511279.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):207-22 [8832463.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):309-17 [3221258.001]
  • [Cites] Childs Nerv Syst. 2004 Mar;20(3):143-53 [14669023.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64 [10192340.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):859-63 [8487066.001]
  • [Cites] Oncologist. 2004;9(2):197-206 [15047924.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):193-205 [8832462.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):545-53 [10550585.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(1):25-31; discussion 31 [2133406.001]
  • [Cites] Pediatr Neurosurg. 1996;24(1):9-23 [8817611.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):185-92 [8873160.001]
  • [Cites] Arch Dis Child. 1999 Jun;80(6):558-64 [10332008.001]
  • (PMID = 16568342.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 5J49Q6B70F / Vincristine
  •  go-up   go-down


22. Puputti M, Tynninen O, Pernilä P, Salmi M, Jalkanen S, Paetau A, Sihto H, Joensuu H: Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors. Brain Pathol; 2010 Jul;20(4):763-70
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors.
  • KIT receptor tyrosine kinase is expressed in tumor endothelial cells of adult glioblastomas, but its expression in pediatric brain tumor endothelial cells is unknown.
  • We assessed expression of KIT, phosphorylated KIT, stem cell factor (SCF) and vascular endothelial growth factor receptor-2 (VEGFR-2) in 35 juvenile pilocytic astrocytomas and 49 other pediatric brain tumors using immunohistochemistry, and KIT messenger RNA (mRNA) using in situ hybridization.
  • KIT and phospho-KIT were present in endothelia of other pediatric brain tumors, notably ependymomas.
  • Endothelial cell KIT expression was associated with a young age at diagnosis of pilocytic astrocytoma or ependymoma, and it was occasionally present in histologically normal tissue of the fetus and children.
  • We conclude that KIT is commonly present in endothelial cells of juvenile brain tumors and thus may play a role in angiogenesis in these neoplasms.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Endothelial Cells / metabolism. Ependymoma / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Humans. Immunohistochemistry. In Situ Hybridization. Infant. Infant, Newborn. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Statistics, Nonparametric. Vascular Endothelial Growth Factor Receptor-2 / genetics. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 May;13(5):536-41 [10824925.001]
  • [Cites] Histopathology. 2009 Nov;55(5):544-53 [19912360.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):486-92 [11914627.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7674-8 [14633689.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18600-7 [14985355.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2397-401 [15150569.001]
  • [Cites] J Comp Neurol. 2004 Jul 19;475(2):247-60 [15211465.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] Cell. 1990 Oct 5;63(1):225-33 [1698557.001]
  • [Cites] Cell. 1990 Oct 5;63(1):235-43 [1698558.001]
  • [Cites] Nature. 1990 Oct 18;347(6294):667-9 [1699134.001]
  • [Cites] Development. 1991 Dec;113(4):1207-21 [1811937.001]
  • [Cites] J Neuropathol Exp Neurol. 1992 Sep;51(5):488-92 [1381413.001]
  • [Cites] Trends Genet. 1993 Aug;9(8):285-90 [7691001.001]
  • [Cites] Development. 1993 Sep;119(1):49-56 [7506140.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 May;54(3):304-10 [7745429.001]
  • [Cites] Brain Res Dev Brain Res. 1995 Apr 18;85(2):201-11 [7541320.001]
  • [Cites] Pediatr Dev Pathol. 2004 Sep-Oct;7(5):493-8 [15547773.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):49-57 [15545668.001]
  • [Cites] J Pathol. 2005 Oct;207(2):224-31 [16021678.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1415-22 [16818499.001]
  • [Cites] J Pathol. 2007 Mar;211(4):481-8 [17294421.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1853-61 [18339685.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1467-72 [11073807.001]
  • (PMID = 20030644.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2901521
  •  go-up   go-down


23. Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY, Zhu Y: Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell; 2009 Jun 2;15(6):514-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model.
  • However, the mechanisms by which alterations of these glioblastoma genes singly and cooperatively transform brain cells remain poorly understood.
  • By targeting a p53 in-frame deletion mutation to the brain, we show that p53 deficiency provides no significant growth advantage to adult brain cells, but appears to induce pleiotropic accumulation of cooperative oncogenic alterations driving gliomagenesis.
  • Our data show that accumulation of a detectable level of mutant p53 proteins occurs first in neural stem cells in the subventricular zone (SVZ) and that subsequent expansion of mutant p53-expressing Olig2(+) transit-amplifying progenitor-like cells in the SVZ-associated areas initiates glioma formation.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Science. 1994 Jul 15;265(5170):346-55 [8023157.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2121-7 [8668337.001]
  • [Cites] J Neurosci. 1997 Jul 1;17(13):5046-61 [9185542.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Nat Neurosci. 2005 Jul;8(7):865-72 [15951811.001]
  • [Cites] Development. 2005 Dec;132(24):5577-88 [16314489.001]
  • [Cites] Development. 2006 Jan;133(2):363-9 [16368933.001]
  • [Cites] J Neurosci. 2006 Jan 25;26(4):1107-16 [16436596.001]
  • [Cites] Mol Cell. 2006 Jun 23;22(6):741-53 [16793544.001]
  • [Cites] J Neurosci. 2006 Jul 26;26(30):7907-18 [16870736.001]
  • [Cites] Curr Opin Cell Biol. 2006 Dec;18(6):704-9 [17046226.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):424-9 [17622647.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Neuron. 2008 Jun 26;58(6):832-46 [18579075.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] Int J Oncol. 2003 Sep;23(3):641-8 [12888899.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3525-32 [15150107.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • (PMID = 19477430.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS053900-03; United States / NINDS NIH HHS / NS / R01 NS053900; United States / NINDS NIH HHS / NS / 1R01 NS053900; United States / NINDS NIH HHS / NS / R01 NS053900-01; United States / NINDS NIH HHS / NS / NS053900-01; United States / NINDS NIH HHS / NS / R01 NS053900-02; United States / NINDS NIH HHS / NS / NS053900-02; United States / NINDS NIH HHS / NS / R01 NS073762; United States / NINDS NIH HHS / NS / NS053900-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS112275; NLM/ PMC2721466
  •  go-up   go-down


24. Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, Neuwelt EA: Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol; 2006 May;77(3):279-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
  • From 1984 to 1998, eight patients (4M/4F), median age 11 years, with DPG were treated with monthly osmotic blood-brain barrier disruption (BBBD) chemotherapy using intraarterial carboplatin or methotrexate and intravenous cytoxan and etoposide.
  • Two patients had biopsies that showed an astrocytoma and an anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Blood-Brain Barrier / metabolism. Brain Stem Neoplasms / drug therapy. Drug Delivery Systems / methods. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Osmosis / drug effects. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 1998 Jul;286(1):77-84 [9655844.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30 [8133987.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):171-7 [9892099.001]
  • [Cites] Med Pediatr Oncol. 1998 Jan;30(1):28-33 [9371386.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):555-62 [8630965.001]
  • [Cites] Neuro Oncol. 2003 Jan;5(1):8-13 [12626128.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):17-27; discussion 27-8 [8587686.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1182-5 [12654425.001]
  • [Cites] Pediatr Neurosurg. 2001 Apr;34(4):206-14 [11359114.001]
  • [Cites] Pediatr Neurosurg. 1996;24(5):263-6 [8933570.001]
  • [Cites] Bull Cancer. 2004 Jun;91(6):E167-83 [15562562.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):685-92 [10649264.001]
  • [Cites] Childs Nerv Syst. 2004 Mar;20(3):143-53 [14669023.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64 [10192340.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):493-500 [11297239.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1064-9 [10491535.001]
  • (PMID = 16314949.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS33618; United States / NINDS NIH HHS / NS / NS34608; United States / NINDS NIH HHS / NS / NS44687
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


25. Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD, Albin MG, Emnett RJ, Loeser S, Watson MA, Nagarajan R, Gutmann DH: Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res; 2007 Feb 1;67(3):890-900
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.
  • Lastly, we also identified a gene expression pattern common to PAs and normal mouse astrocytes and neural stem cells from these distinct brain regions as well as a gene expression pattern shared between PAs and another human glial tumor (ependymoma) arising supratentorially compared with those originating in the posterior fossa.
  • These results suggest that glial tumors share an intrinsic, lineage-specific molecular signature that reflects the brain region in which their nonmalignant predecessors originated.
  • [MeSH-major] Astrocytoma / genetics. Infratentorial Neoplasms / genetics. Supratentorial Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Algorithms. Child. Child, Preschool. Cluster Analysis. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / metabolism. Neurofibromatosis 1 / pathology. Oligonucleotide Array Sequence Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283119.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE5582/ GSE5675
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 91842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Phi JH, Chung CK: Brain tumors in the mesial temporal lobe: long-term oncological outcome. Neurosurg Focus; 2009 Aug;27(2):E5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumors in the mesial temporal lobe: long-term oncological outcome.
  • OBJECT: Surgical treatment of brain tumors in the mesial temporal lobe (MTL) is a highly demanding procedure.
  • Extension of the tumor into the fusiform gyrus (Schramm Type C) and temporal stem (Schramm Type D) was observed in 4 and 7 patients (11 and 19%), respectively.
  • All tumors were low-grade lesions except for 1 anaplastic astrocytoma.
  • [MeSH-major] Brain Neoplasms / surgery. Temporal Lobe / surgery
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Disease-Free Survival. Epilepsy / etiology. Epilepsy / surgery. Female. Follow-Up Studies. Functional Laterality. Ganglioglioma / pathology. Ganglioglioma / surgery. Humans. Longitudinal Studies. Male. Middle Aged. Neurosurgical Procedures. Outcome Assessment (Health Care). Prognosis. Proportional Hazards Models

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645561.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Pascual-Castroviejo I, Pascual-Pascual SI, Viaño J, Carceller F, Gutierrez-Molina M, Morales C, Frutos-Martinez R: Posterior fossa tumors in children with neurofibromatosis type 1 (NF1). Childs Nerv Syst; 2010 Nov;26(11):1599-603
Genetic Alliance. consumer health - Neurofibromatosis type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four of them had astrocytomas but only in one case was the tumour primarily cerebellar while the tumour was primarily of the brain stem with invasion of the adjacent regions of one or both cerebellar hemispheres in three patients.
  • The patient with primary cerebellar astrocytoma is apparently cured 7 years after the removal of the tumour.
  • The patients with the brain stem tumours extending to the cerebellum, showed a chronic slowly progressive cerebellar disease, but remain alive at age of more than 20 years (one was lost to follow-up).
  • This location is very uncommon in patients with NF1, in contrast with those located in other regions, such as pathway optic tumours and brain stem tumours.
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / diagnosis. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Brain Stem Neoplasms / diagnosis. Brain Stem Neoplasms / mortality. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / mortality. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male. Medulloblastoma / diagnosis. Medulloblastoma / mortality. Medulloblastoma / pathology. Medulloblastoma / surgery. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2010 Nov;26(11):1491; author reply 1493 [20853110.001]
  • [Cites] Rev Neurol. 2010 Apr 16;50(8):453-7 [20414870.001]
  • [Cites] Childs Nerv Syst. 2007 Oct;23 (10 ):1191-4 [17457593.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):417-20 [10958550.001]
  • [Cites] Neuroradiology. 2004 Oct;46(10):825-9 [15289955.001]
  • [Cites] Cancer. 1977 Oct;40(4 Suppl):1903-11 [198110.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):827-9 [11294917.001]
  • [Cites] Neurologia. 2007 Dec;22(10):846-52 [17671854.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1969 Feb;32(1):43-7 [4975362.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] Pathol Annu. 1985;20 Pt 1:331-58 [3921930.001]
  • [Cites] Rev Neurol. 2008 May 1-15;46(9):530-6 [18446694.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):885-90 [11294925.001]
  • [Cites] Rev Neurol. 2008 Aug 1-15;47(3):129-33 [18654966.001]
  • [Cites] Neuroradiology. 1997 Sep;39(9):639-41 [9335062.001]
  • (PMID = 20464401.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer; 2007 Oct 1;110(7):1542-50
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors.
  • PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET).
  • No responses were observed in patients with ependymoma, brain-stem glioma, or other CNS tumors.
  • Notably, 41% of patients with low-grade astrocytoma had SD through 12 courses.
  • CONCLUSIONS: Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Humans. Infant. Male. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Treatment Outcome


29. Elgamal EA, Coakham HB: Hemifacial spasm caused by pontine glioma: case report and review of the literature. Neurosurg Rev; 2005 Oct;28(4):330-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemifacial spasm (HFS) is an involuntary paroxysmal contractions of the facial musculature, caused generally by vascular compression of the seventh cranial nerve at its root exit zone from the brain stem.
  • The case of an adult man harbouring brain stem glioma (BSG) whose only neurological signs were left HFS and mild facial weakness is reported.
  • No responsible vessel could be identified during surgery, but the causative lesion was found to be an astrocytic tumour encasing the facial nerve at its root exit zone from the brain stem.
  • [MeSH-major] Astrocytoma / complications. Brain Stem Neoplasms / complications. Hemifacial Spasm / etiology

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Hemifacial Spasm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1977 Sep;47(3):321-8 [894338.001]
  • [Cites] Neurosurgery. 1993 Jun;32(6):1031-4 [8327079.001]
  • [Cites] Arch Neurol. 1976 Apr;33(4):302-3 [1259646.001]
  • [Cites] Acta Neurochir (Wien). 1995;134(3-4):148-54 [8748774.001]
  • [Cites] Can J Ophthalmol. 1991 Apr;26(3):148-51 [2054726.001]
  • [Cites] Arch Ophthalmol. 1990 Jun;108(6):812-5 [2350284.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Jun;100(2):104-11 [9746297.001]
  • [Cites] J Neurol. 1996 Apr;243(4):367-8 [8965114.001]
  • [Cites] Rev Neurol (Paris). 1999 Apr;155(4):309-11 [10367329.001]
  • [Cites] Pediatr Neurol. 1999 Oct;21(4):754-6 [10580892.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):134-7 [2045898.001]
  • [Cites] Mayo Clin Proc. 1986 Aug;61(8):640-4 [3724243.001]
  • (PMID = 16001287.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Mursch K, Halatsch ME, Markakis E, Behnke-Mursch J: Intrinsic brainstem tumours in adults: results of microneurosurgical treatment of 16 consecutive patients. Br J Neurosurg; 2005 Apr;19(2):128-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrinsic brainstem tumours in adults: results of microneurosurgical treatment of 16 consecutive patients.
  • Intrinsic brainstem tumours in adults have a poor prognosis and surgical resection is rarely performed.
  • Eight patients had from WHO grade II astrocytoma and a similar course as patients with higher-grade gliomas (n = 4).
  • Our results indicate that open microneurosurgery for intrinsic brainstem tumours is of questionable benefit for the patient.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Glioma / surgery. Microsurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / mortality. Astrocytoma / surgery. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120515.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Hu WW, Zheng XJ, Shen G, Liu WG, Shen H, Fu WM, Zhou JY: [Diagnosis and micro-neurosurgery for the fourth cerebral ventricle tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Feb;29(2):144-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathology included 32 medulloblastomas, 23 ependymoma, 15 astrocytoma, 10 hemangiblastomas, 2 choroid plexus papillomas, and 4 epidermoid cysts.
  • CONCLUSION: Medulloblastoma, astrocytoma and hemangiblastoma are suggested to be removed totally whenever technically possible according to the site, character and volume of the tumor.
  • For ependymoma, if close to the brain stem, is recommended to be subtotally removed.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / radiography. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Ependymoma / diagnosis. Ependymoma / radiography. Ependymoma / surgery. Female. Follow-Up Studies. Hemangioblastoma / diagnosis. Hemangioblastoma / radiography. Hemangioblastoma / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645855.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Pantelis E, Papadakis N, Verigos K, Stathochristopoulou I, Antypas C, Lekas L, Tzouras A, Georgiou E, Salvaras N: Integration of functional MRI and white matter tractography in stereotactic radiosurgery clinical practice. Int J Radiat Oncol Biol Phys; 2010 Sep 1;78(1):257-67
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: fMRI and tractography data sets were acquired and fused with corresponding anatomical MR and computed tomography images of patients with arteriovenous malformation (AVM), astrocytoma, brain metastasis, or hemangioma and referred for stereotactic radiosurgery.
  • In the astrocytoma case, the dose to the motor cortex bordering the lesion was reduced to 1,900 cGy from 2,100 cGy, and therefore, the biologically equivalent dose in three fractions was delivered instead.
  • [MeSH-major] Brain Neoplasms. Intracranial Arteriovenous Malformations. Magnetic Resonance Imaging / methods. Radiation Injuries / prevention & control. Radiosurgery / methods
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / radiography. Astrocytoma / surgery. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / radiography. Brain Stem Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Diffusion Tensor Imaging / methods. Female. Hemangioma, Cavernous, Central Nervous System / pathology. Hemangioma, Cavernous, Central Nervous System / radiography. Hemangioma, Cavernous, Central Nervous System / surgery. Humans. Lung Neoplasms / pathology. Male. Middle Aged. Motor Cortex / anatomy & histology. Motor Cortex / radiation effects. Motor Cortex / radiography. Pyramidal Tracts / anatomy & histology. Pyramidal Tracts / radiation effects. Pyramidal Tracts / radiography. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted / methods. Visual Pathways / anatomy & histology. Visual Pathways / radiation effects. Visual Pathways / radiography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20421146.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Salgado JV, Costa-Silva M, Malloy-Diniz LF, Siqueira JM, Teixeira AL: Prefrontal cognitive dysfunction following brainstem lesion. Clin Neurol Neurosurg; 2007 May;109(4):379-82
Hazardous Substances Data Bank. METHYLPHENIDATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prefrontal cognitive dysfunction following brainstem lesion.
  • As ascending monoaminergic brainstem systems modulate PFC functioning, it is possible that lesions in the brainstem lead to symptoms similar to prefrontal dysfunction.
  • A 29-year-old man developed several cognitive and behavioral symptoms after neurosurgery for resection of a pilocytic astrocytoma in the pontine-mesencephalic area.
  • A careful analysis of symptoms indicated PFC dysfunction that could be attributed to lesions in the ascending monoaminergic brainstem systems.
  • This is a unique case of PFC dysfunction that may be related to post-operative lesion of the catecholaminergic nuclei in the brainstem.
  • [MeSH-major] Astrocytoma / surgery. Brain Stem Neoplasms / surgery. Cognition Disorders / physiopathology. Postoperative Complications / physiopathology. Prefrontal Cortex / physiopathology
  • [MeSH-minor] Adolescent. Adult. Attention / drug effects. Attention / physiology. Central Nervous System Stimulants / therapeutic use. Educational Status. Follow-Up Studies. Humans. Impulsive Behavior / diagnosis. Impulsive Behavior / drug therapy. Impulsive Behavior / physiopathology. Inhibition (Psychology). Interpersonal Relations. Learning Disorders / diagnosis. Learning Disorders / drug therapy. Learning Disorders / physiopathology. Male. Methylphenidate / therapeutic use. Neuropsychological Tests. Problem Solving / drug effects. Problem Solving / physiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17275997.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  •  go-up   go-down


34. Miki T, Nakajima N, Akimoto J, Wada J, Haraoka J: Neuroendoscopic trans-third ventricle approach for lesions of the ventral brainstem surface. Minim Invasive Neurosurg; 2008 Dec;51(6):313-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendoscopic trans-third ventricle approach for lesions of the ventral brainstem surface.
  • Due to the establishment in recent years of neuroendoscopic third ventriculostomy (ETV), it has become possible during ETV to observe the ventral brainstem surface--particularly the prepontine cistern--in a minimally invasive manner via the third ventricular base with a neuroendoscope.
  • As an adaptation of that technique in this study, we investigated a neuroendoscopic trans-third ventricle approach (ETTVA), which accesses lesions of the ventral brainstem surface with a neuroendoscope inserted via the stoma of the third ventricular floor.
  • Our study included 6 cases, including one case each of neurenteric cyst, chordoma, pontine glioma (astrocytoma), ecchordosis physaliphora, endodermal cyst, and cystic schwannoma.
  • [MeSH-major] Astrocytoma / surgery. Brain Stem Neoplasms / surgery. Chordoma / surgery. Minimally Invasive Surgical Procedures / methods. Neuroendoscopy / methods. Third Ventricle / surgery. Ventriculostomy / methods
  • [MeSH-minor] Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / methods. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061139.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Chen H, Huang Q, Zhai DZ, Dong J, Wang AD, Lan Q: [CDK1 expression and effects of CDK1 silencing on the malignant phenotype of glioma cells]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):484-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Our previous cDNA array data have shown that expression level of CDK1 increased along with the malignant progression of ganglioglioma, and decreased with the differentiation process of neural stem cells.
  • METHODS: Glioma tissue array was constructed, which was composed of surgical specimens of gliomas with different malignancy grades, glioma xenografts in nude mice, cellular spheroids of brain tumor stem cells, normal neural stem cells and glioma cell line.
  • CDK1 expression in human brain glioma cell line and relevant xenogeneic graft tumor was inhibited by retroviral vectors expressing short hairpin RNAs (shRNAs).
  • The positive expression rates of CDK1 in human brain glioma tissues were 22.2% (grade I), 40.0% (grade II), 69.6% (grade III) and 78.6% (grade IV), P = 0.01, respectively.
  • The positive expression rate of CDK1 in glioma cell line and implanted xenografts was similar as the clinical tumors with high malignancy, and higher than those in neural stem cells and brain tumor stem cells (P = 0.0014).
  • Expression of CDK1 was high in human fetal brain tissues and bone marrows of nude mice, but low in normal adult human brain tissues.
  • [MeSH-major] Brain Neoplasms / metabolism. CDC2 Protein Kinase / metabolism. Cell Differentiation / drug effects. Gene Silencing. Glioma / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Stem Neoplasms / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Ganglioglioma / genetics. Ganglioglioma / metabolism. Ganglioglioma / pathology. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Nude. Neoplasm Staging. Neoplasm Transplantation. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069625.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


36. Murai N, Kaneko T: [Case of jugular foramen schwannoma associated with tuberous sclerosis]. No Shinkei Geka; 2007 Oct;35(10):1007-11
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her tuberous sclerosis was diagnosed at the age of 9, when she developed hydrocephalus caused by subependymal giant cell astrocytoma near the foramen of Monro, which was treated by surgical resection and VP shunt placement followed by radiation and chemotherapy.
  • Brain MR images revealed a 3 cm enhancing mass extending from the left jugular foramen to the cerebellopontine cistern, accompanied by perifocal edema of the brain stem and cerebellar hemisphere.
  • [MeSH-minor] Adult. Astrocytoma / etiology. Astrocytoma / therapy. Cerebral Ventricle Neoplasms / etiology. Cerebral Ventricle Neoplasms / therapy. Cerebral Ventricles. Female. Humans. Hydrocephalus / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969337.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Rush SZ, Abel TW, Valadez JG, Pearson M, Cooper MK: Activation of the Hedgehog pathway in pilocytic astrocytomas. Neuro Oncol; 2010 Aug;12(8):790-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilocytic astrocytoma is commonly viewed as a benign lesion.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2009 May 21;28(20):2119-23 [19363522.001]
  • [Cites] Acta Neuropathol. 2009 Jun;117(6):657-65 [19271226.001]
  • [Cites] Mol Carcinog. 2009 Aug;48(8):703-12 [19142899.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):417-23 [19479971.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3691-7 [19581535.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] Oncogene. 2009 Oct 1;28(39):3468-76 [19617900.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):44-51 [10564585.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1569-76 [11013373.001]
  • [Cites] Pediatr Neurosurg. 2001 Dec;35(6):311-7 [11786699.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):306-10 [12068298.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6 [12391318.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2968-73 [12885817.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Neurology. 2004 Apr 27;62(8):1311-6 [15111667.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] J Neurosurg. 1988 Jan;68(1):41-7 [3335911.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):171-6 [3392563.001]
  • [Cites] Neurosurgery. 1992 Sep;31(3):413-8; discussion 419 [1407423.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2085-8 [9187099.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2581-5 [9205058.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):9-16 [9525833.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):265-73 [9950497.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):833-6 [9989836.001]
  • [Cites] Neuropathol Appl Neurobiol. 1999 Apr;25(2):134-42 [10216001.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5198-204 [16051961.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):839-45 [16424016.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):187-97 [16459298.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Childs Nerv Syst. 2007 May;23(5):543-7 [17226033.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5752-61 [17353902.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2524-33 [17628016.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1284-92 [19190345.001]
  • [Cites] Trends Pharmacol Sci. 2009 Jun;30(6):303-12 [19443052.001]
  • (PMID = 20223881.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA068485; United States / NINDS NIH HHS / NS / K02NS053614
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0 / patched receptors
  • [Other-IDs] NLM/ PMC2940682
  •  go-up   go-down


38. Suzuki Y, Tanaka K, Negishi D, Shimizu M, Yoshida Y, Hashimoto T, Yamazaki H: Pharmacokinetic investigation of increased efficacy against malignant gliomas of carboplatin combined with hyperbaric oxygenation. Neurol Med Chir (Tokyo); 2009 May;49(5):193-7; discussion 197
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of intravenous administration of 400 mg carboplatin/m(2) body surface area over 60 minutes combined with hyperbaric oxygenation (HBO) therapy (0.2 MPa for 60 min) was investigated in 6 Japanese patients (aged 36-67 years) with malignant or brainstem gliomas.
  • Brain tumor response was evaluated by magnetic resonance imaging as a function of maximum plasma concentration, area under the curve, or mean residence time (MRT) for carboplatin.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / therapy. Carboplatin / therapeutic use. Glioblastoma / therapy. Hyperbaric Oxygenation
  • [MeSH-minor] Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / surgery. Astrocytoma / therapy. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / radiotherapy. Brain Stem Neoplasms / surgery. Brain Stem Neoplasms / therapy. Chromatography, High Pressure Liquid. Combined Modality Therapy. Cranial Irradiation. Drug Synergism. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465788.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; BG3F62OND5 / Carboplatin
  •  go-up   go-down


39. Chen X, Weigel D, Ganslandt O, Buchfelder M, Nimsky C: Diffusion tensor imaging and white matter tractography in patients with brainstem lesions. Acta Neurochir (Wien); 2007 Nov;149(11):1117-31; discussion 1131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion tensor imaging and white matter tractography in patients with brainstem lesions.
  • BACKGROUND: Diffusion tensor imaging (DTI) and white matter tractography (WMT) are promising techniques for estimating the course, extent, and connectivity patterns of the white matter (WM) structures in the human brain.
  • In this study, we investigated the ability of DTI and WMT to visualize white matter tract involvement for the preoperative surgical planning and postoperative assessment of brainstem lesions.
  • METHODS: Preoperative and postoperative DTI data (echo-planar, 1.5T) were retrospectively analyzed in 10 patients with brainstem lesions (3 diffuse, 7 focal).
  • CONCLUSIONS: Compared with the information provided by conventional MR imaging, DTI and WMT provided superior quantification and visualization of lesion involvement in eloquent fibre tracts of the brainstem.
  • Moreover, DTI and WMT were found to be beneficial for white matter recognition in the neurosurgical planning and postoperative assessment of brainstem lesions.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Mapping. Brain Stem Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging. Hemangioma, Cavernous, Central Nervous System / diagnosis. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Nerve Fibers, Myelinated / pathology. Nerve Net / pathology. Neuronavigation. Pons / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Damage, Chronic / diagnosis. Brain Damage, Chronic / pathology. Brain Damage, Chronic / surgery. Cranial Nerve Diseases / diagnosis. Cranial Nerve Diseases / pathology. Dominance, Cerebral / physiology. Female. Humans. Male. Middle Aged. Neurologic Examination. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Pyramidal Tracts / pathology. Pyramidal Tracts / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712509.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


40. Christensen K, Schrøder HD, Kristensen BW: CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol; 2008 Nov;90(2):157-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to investigate the localization and distribution of the putative brain tumour stem cell marker CD133 in formalin fixed paraffin embedded astrocytomas.
  • In conclusion, a CD133(+) perivascular stem cell-like entity exists in astrocytomas.
  • CD133(+) tumour vessels may play an important role in a brain tumour stem cell context, while CD133 alone does not appear to be a specific tumour stem cell marker related to patient survival.
  • [MeSH-major] Antigens, CD / metabolism. Astrocytoma / pathology. Brain Neoplasms / pathology. Endothelium, Vascular / metabolism. Glycoproteins / metabolism. Peptides / metabolism
  • [MeSH-minor] AC133 Antigen. Adolescent. Adult. Aged. Analysis of Variance. Child. Child, Preschool. Female. Humans. Indoles. Intermediate Filament Proteins / metabolism. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Nestin. Retrospective Studies. Survival Analysis. Ubiquitin-Protein Ligases / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2004 Jul;17(7):790-7 [15073602.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] J Comp Neurol. 2000 Oct 2;425(4):479-94 [10975875.001]
  • [Cites] Cell Tissue Res. 2005 Jan;319(1):15-26 [15558321.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Am J Clin Pathol. 2008 Mar;129(3):358-66 [18285257.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14 (1):123-9 [18172261.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):702-5 [12033959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16466-71 [17056721.001]
  • [Cites] Science. 2004 May 28;304(5675):1338-40 [15060285.001]
  • [Cites] Cell. 2004 Mar 19;116(6):769-78 [15035980.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3560-4 [17440065.001]
  • [Cites] Int J Cancer. 2004 Oct 10;111(6):921-8 [15300804.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23 ):10946-51 [16322242.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10 ):733-6 [17882276.001]
  • [Cites] PLoS One. 2008 Apr 09;3(4):e1936 [18398462.001]
  • [Cites] Acta Cytol. 1989 Sep-Oct;33(5):576-82 [2476903.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):373-85 [1503912.001]
  • [Cites] APMIS. 1988 May;96(5):379-94 [3288247.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Acta Neurol Scand Suppl. 1992;137:8-13 [1357908.001]
  • [Cites] Neurosurgery. 2008 Feb;62(2):505-14; discussion 514-5 [18382330.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):908-13 [17512905.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] J Histochem Cytochem. 1997 Nov;45(11):1455-9 [9358847.001]
  • [Cites] Acta Neurochir (Wien). 1986;81(3-4):132-4 [3751697.001]
  • [Cites] Clin Neuropathol. 2004 Mar-Apr;23(2):47-52 [15074577.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):965-9 [15333659.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23 (6):791-804 [15917475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] J Microsc. 1986 Jul;143(Pt 1):3-45 [3761363.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] J Microsc. 1987 Sep;147(Pt 3):229-63 [3430576.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):31-45 [17611714.001]
  • [Cites] Differentiation. 2001 Sep;68(2-3):141-52 [11686236.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12 ):5727-36 [17575139.001]
  • (PMID = 18612800.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 Antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Indoles; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / PROM1 protein, human; 0 / Peptides; 47165-04-8 / DAPI; EC 2.3.2.27 / MIB1 ligase, human; EC 2.3.2.27 / Ubiquitin-Protein Ligases
  •  go-up   go-down


41. Ramírez-Zamora A, Biller J: Brainstem cavernous malformations: a review with two case reports. Arq Neuropsiquiatr; 2009 Sep;67(3B):917-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem cavernous malformations: a review with two case reports.
  • We present one case of 'de novo' brainstem cavernous malformation after radiation therapy adding to the increasing number of reported cases in the medical literature, and the case of a pregnant patient with symptomatic intracranial hemorrhage related to brainstem CMs to illustrate the complex nature in management of these patients, followed by a review of clinical and radiographic characteristics.
  • [MeSH-major] Brain Stem. Cerebral Hemorrhage / etiology. Intracranial Arteriovenous Malformations / diagnosis. Pregnancy Complications, Cardiovascular / diagnosis
  • [MeSH-minor] Adult. Astrocytoma / radiotherapy. Cerebellar Neoplasms / radiotherapy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Pregnancy. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838533.001).
  • [ISSN] 1678-4227
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 40
  •  go-up   go-down


42. Komatani H, Sugita Y, Arakawa F, Ohshima K, Shigemori M: Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: an accelerated growth factor in glioblastomas. Int J Oncol; 2009 Mar;34(3):665-72
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CXCL12, an alpha-chemokine that binds to G-protein-coupled CXCR4, plays an important and unique role in the regulation of stem/progenitor cell trafficking.
  • Several cell lines of brain tumors were also analyzed by RT-PCR analyses.
  • [MeSH-major] Brain Neoplasms / blood supply. Chemokine CXCL12 / biosynthesis. Glioblastoma / blood supply
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / blood supply. Astrocytoma / pathology. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Child. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212671.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chemokine CXCL12
  •  go-up   go-down


43. Andres RH, Pendharkar AV, Kuhlen D, Mariani L: Ventricular enlargement due to acute hypernatremia in a patient with a ventriculoperitoneal shunt. J Neurosurg; 2010 Jul;113(1):82-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although rare, the effects of acute severe hypernatremia on brain volume and ventricular size should be considered in the differential diagnosis of ventriculoperitoneal shunt failure.
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Agents / administration & dosage. Astrocytoma / complications. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Stem Neoplasms / complications. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Cranial Irradiation. Diagnosis, Differential. Diagnostic Errors. Equipment Failure Analysis. Humans. Hypertrophy. Male. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / radiotherapy. Pituitary Neoplasms / complications. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / radiotherapy. Tectum Mesencephali

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911884.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidiuretic Agents; 0 / Antineoplastic Agents; ENR1LLB0FP / Deamino Arginine Vasopressin
  •  go-up   go-down


44. Kawasaki A, Miller NR, Kardon R: Pupillographic investigation of the relative afferent pupillary defect associated with a midbrain lesion. Ophthalmology; 2010 Jan;117(1):175-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / complications. Brain Injuries / complications. Brain Stem Infarctions / complications. Pinealoma / complications. Pupil / radiation effects. Pupil Disorders / diagnosis. Pupil Disorders / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnostic Techniques, Ophthalmological. Humans. Light. Middle Aged. Photic Stimulation. Visual Acuity. Visual Fields

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19923003.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


45. Cao Z, Lv J, Wei X, Quan W: Appliance of preoperative diffusion tensor imaging and fiber tractography in patients with brainstem lesions. Neurol India; 2010 Nov-Dec;58(6):886-90
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appliance of preoperative diffusion tensor imaging and fiber tractography in patients with brainstem lesions.
  • BACKGROUND: Surgical resection of brainstem lesions has a high risk of morbidity, because vital fasciculi in the brainstem can be damaged along the entry routes.
  • Diffusion tensor imaging (DTI) is an in vivo method for mapping white matter fiber tracts in the brain.
  • OBJECTIVE: To summarize the experience of surgical treatment of brainstem lesions with the assistance of DTI and fiber tractography.
  • MATERIALS AND METHODS: A retrospective analysis clinical data of nine patients with brainstem lesions were investigated between July 2007 and September 2009.
  • Total resection was achieved in two patients with brainstem cavernomas and two patients with pilocytic astrocytoma.
  • The neurological functional status was better than preoperative period in eight patients, one patient with medulla oblongata astrocytoma deteriorated.
  • CONCLUSIONS: DTI and fiber tractography can provide valuable information regarding the relationship between the principal fiber tracts and brainstem lesions, which is useful in neurosurgical planning.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Mapping. Brain Stem / pathology. Diffusion Tensor Imaging. Pyramidal Tracts / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Imaging, Three-Dimensional. Male. Neurosurgery / methods. Preoperative Care. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150055.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


46. Ramat S, Leigh RJ, Zee DS, Optican LM: Ocular oscillations generated by coupling of brainstem excitatory and inhibitory saccadic burst neurons. Exp Brain Res; 2005 Jan;160(1):89-106
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular oscillations generated by coupling of brainstem excitatory and inhibitory saccadic burst neurons.
  • Previous models proposed that high-frequency eye oscillations produced by the saccadic system (saccadic oscillations), occur because of a delay in a negative feedback loop around high-gain, excitatory burst neurons in the brainstem.
  • We propose another model that accounts for saccadic oscillations based on 1) coupling of excitatory and inhibitory burst neurons in the brainstem and 2) the hypothesis that burst neurons show post-inhibitory rebound discharge.
  • [MeSH-major] Astrocytoma / physiopathology. Biological Clocks / physiology. Brain Stem / physiology. Cerebellar Neoplasms / physiopathology. Cerebellar Nuclei / physiology. Neurons / physiology. Saccades / physiology
  • [MeSH-minor] Adult. Feedback / physiology. Humans. Male. Middle Aged. Models, Neurological. Nerve Net / physiology. Nerve Net / physiopathology. Neural Inhibition / physiology. Neural Pathways / physiology. Neural Pathways / physiopathology. Ocular Motility Disorders / etiology. Ocular Motility Disorders / physiopathology. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Psychomotor Performance / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurobiol. 1995 Dec;5(6):763-8 [8805411.001]
  • [Cites] Ann Neurol. 1986 Mar;19(3):299-301 [3963775.001]
  • [Cites] J Neuroophthalmol. 1994 Jun;14(2):95-101 [7951936.001]
  • [Cites] Baillieres Clin Neurol. 1992 Aug;1(2):263-87 [1344070.001]
  • [Cites] Neural Netw. 1998 Oct;11(7-8):1175-1190 [12662742.001]
  • [Cites] J Neurophysiol. 1998 Jun;79(6):2895-902 [9636095.001]
  • [Cites] Biol Cybern. 1981;39(2):87-96 [7236748.001]
  • [Cites] Ann Neurol. 1979 May;5(5):405-14 [111605.001]
  • [Cites] Annu Rev Neurosci. 2001;24:981-1004 [11520925.001]
  • [Cites] Rev Oculomot Res. 1989;3:105-212 [2486322.001]
  • [Cites] J Neurosci. 2000 Mar 1;20(5):1735-45 [10684875.001]
  • [Cites] J Neurophysiol. 2002 Feb;87(2):679-95 [11826037.001]
  • [Cites] Trends Neurosci. 1998 Nov;21(11):451-2 [9829683.001]
  • [Cites] J Comp Neurol. 1986 Jul 15;249(3):358-80 [3734161.001]
  • [Cites] J Neurophysiol. 1988 May;59(5):1455-75 [3385469.001]
  • [Cites] Ann N Y Acad Sci. 2002 Apr;956:164-77 [11960802.001]
  • [Cites] J Comp Neurol. 1995 Aug 21;359(2):350-63 [7499534.001]
  • [Cites] J Am Optom Assoc. 1995 Jul;66(7):419-22 [7560729.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1681-6 [10393036.001]
  • [Cites] Biomed Sci Instrum. 1995;31:53-8 [7654983.001]
  • [Cites] J Neurophysiol. 1999 Oct;82(4):1697-709 [10515960.001]
  • [Cites] J Neurophysiol. 1999 Aug;82(2):999-1018 [10444693.001]
  • [Cites] Am J Otol. 1992 Mar;13(2):152-7 [1599008.001]
  • [Cites] J Neurophysiol. 1993 Nov;70(5):1741-58 [8294950.001]
  • [Cites] Neuroscience. 1995 Oct;68(4):1059-77 [8544982.001]
  • [Cites] J Comp Neurol. 1988 Jan 15;267(3):307-21 [2830321.001]
  • [Cites] J Neurophysiol. 1974 Mar;37(2):316-32 [4205567.001]
  • [Cites] J Neurophysiol. 1982 May;47(5):827-44 [7086471.001]
  • [Cites] J Neurophysiol. 2001 Sep;86(3):1365-75 [11535683.001]
  • [Cites] J Physiol. 1964 Nov;174:245-64 [14244121.001]
  • [Cites] J Neurophysiol. 2003 Dec;90(6):3838-53 [12930821.001]
  • [Cites] Arch Ophthalmol. 1977 Aug;95(8):1399-404 [889517.001]
  • [Cites] J Neurophysiol. 1997 Aug;78(2):1120-34 [9307139.001]
  • [Cites] J Neurosci. 2002 Mar 15;22(6):2083-95 [11896148.001]
  • [Cites] Eur J Neurosci. 1990;2(1):11-23 [12106099.001]
  • [Cites] Exp Brain Res. 2002 Feb;142(4):439-62 [11845241.001]
  • [Cites] J Neurophysiol. 2002 Jan;87(1):257-72 [11784748.001]
  • [Cites] J Neurol Sci. 2001 Aug 15;189(1-2):71-81 [11535236.001]
  • [Cites] Physiol Rev. 2003 Jan;83(1):117-61 [12506128.001]
  • [Cites] J Comp Neurol. 1986 Jul 15;249(3):337-57 [3734160.001]
  • [Cites] Nat Rev Neurosci. 2002 Dec;3(12):952-64 [12461552.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Mar;42(3):660-7 [11222524.001]
  • [Cites] J Neurophysiol. 1981 Mar;45(3):417-42 [7218009.001]
  • [Cites] Biol Cybern. 1978 Mar 3;28(4):209-21 [204366.001]
  • [Cites] J Neurophysiol. 1988 May;59(5):1430-54 [3385468.001]
  • [Cites] Ann Neurol. 2001 Jan;49(1):24-8 [11198292.001]
  • [Cites] J Neurophysiol. 1985 Jul;54(1):11-27 [4031978.001]
  • [Cites] Brain Res. 1984 Mar 5;294(2):299-304 [6704727.001]
  • [Cites] Science. 1999 Jan 22;283(5401):541-3 [9915702.001]
  • [Cites] J Neurophysiol. 1992 Nov;68(5):1624-41 [1479435.001]
  • [Cites] Bibl Ophthalmol. 1972;82:7-16 [4631298.001]
  • (PMID = 15289966.001).
  • [ISSN] 0014-4819
  • [Journal-full-title] Experimental brain research
  • [ISO-abbreviation] Exp Brain Res
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY01849; United States / NEI NIH HHS / EY / EY06717
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  •  go-up   go-down


47. Sharma MS, Kondziolka D, Khan A, Kano H, Niranjan A, Flickinger JC, Lunsford LD: Radiation tolerance limits of the brainstem. Neurosurgery; 2008 Oct;63(4):728-32; discussion 732-3
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation tolerance limits of the brainstem.
  • OBJECTIVE: One of the key limitations of gamma knife surgery arises from the radiation safety tolerance limit of the brainstem.
  • The authors conducted an analysis of patients with intra-axial brainstem lesions and documented the incidence of adverse radiation imaging effects (ARIE) and new neurological deficits after gamma knife surgery.
  • METHODS: Thirty-eight patients (39 lesions) with intra-axial brainstem astrocytomas or vascular malformations underwent gamma knife surgery during a 6-year interval.
  • Brainstem exposure volume was calculated by subtracting the volume within the 12-Gy isodose line (12 Gray volume) from the prescription volume.
  • RESULTS: The average prescription volume was 1.46 cm, 12 Gy volume was 2.03 cm, and brainstem exposure volume was 0.57 cm.
  • CONCLUSION: Exposure of the brainstem to more than 12 Gy at volumes as low as 0.1 cm can produce ARIE and new neurological deficits.
  • The tolerance of the brainstem to radiosurgery is related to patient age, lesion volume, and pathology.
  • Analysis of the exposed volume of brainstem tissue may be useful in radiosurgical planning for individual patients.
  • [MeSH-major] Astrocytoma / surgery. Brain Stem / radiation effects. Brain Stem Neoplasms / surgery. Ganglioglioma / surgery. Nervous System Diseases / etiology. Radiation Injuries / etiology. Radiosurgery / adverse effects
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Humans. Intracranial Arteriovenous Malformations / surgery. Male. Middle Aged. Retrospective Studies. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981883.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Salmaggi A, Fariselli L, Milanesi I, Lamperti E, Silvani A, Bizzi A, Maccagnano E, Trevisan E, Laguzzi E, Rudà R, Boiardi A, Soffietti R, Associazione Italiana di Neuro-oncologia: Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol; 2008 Feb;255(2):171-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history and management of brainstem gliomas in adults. A retrospective Italian study.
  • Brainstem gliomas in adults are rare tumors, with heterogeneous clinical course; only a few studies in the MRI era describe the features in consistent groups of patients.
  • In this retrospective study, we report clinical features at onset, imaging characteristics and subsequent course in a group of 34 adult patients with either histologically proven or clinico-radiologically diagnosed brainstem gliomas followed at two centers in Northern Italy.
  • In 21 of the patients histology was obtained and in 20 it was informative (2 pilocytic astrocytoma, 9 low-grade astrocytoma, 8 anaplastic astrocytoma and 1 glioblastoma).
  • Compared with literature data, our study confirms the clinical and radiological heterogeneity of adult brainstem gliomas and underscores the need for multicenter trials in order to assess the efficacy of treatments in these tumors.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / therapy. Glioma / pathology. Glioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain / pathology. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Image Processing, Computer-Assisted. Italy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Retrospective Studies. Spinal Cord / pathology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2006 Feb;104(2 Suppl):108-14 [16506498.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):711-5 [11723378.001]
  • [Cites] Neurosurg Rev. 2005 Oct;28(4):330-2 [16001287.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1991;53:148-58 [1803873.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31 [15850898.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):235-41 [8420871.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1266-72 [16525181.001]
  • [Cites] Neurology. 1998 Oct;51(4):1136-9 [9781543.001]
  • [Cites] Acta Neurochir (Wien). 1986;79(2-4):67-73 [3962745.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]
  • [Cites] Neurochirurgie. 1989;35(1):41-6 [2654682.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):757-60 [2004952.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18293027.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


49. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B: Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther; 2006 Mar;5(1):40-7
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
  • BACKGROUND: Brainstem glioma carries the worst prognosis of all malignancies of the brain.
  • Most patients with brainstem glioma fail standard radiation therapy and chemotherapy and do not survive longer than 2 years.
  • RESULTS: The overall survival at 2 and 5 years was 39% and 22%, respectively, and maximum survival was more than 17 years for a patient with anaplastic astrocytoma and more than 5 years for a patient with glioblastoma.
  • CONCLUSION: Antineoplastons contributed to more than a 5-year survival in recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem in a small group of patients.
  • [MeSH-major] Benzeneacetamides / administration & dosage. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Glutamine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Phenylacetates / administration & dosage. Piperidones / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Combinations. Female. Follow-Up Studies. Humans. Injections, Intravenous. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484713.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzeneacetamides; 0 / Drug Combinations; 0 / Phenylacetates; 0 / Piperidones; 0RH81L854J / Glutamine; 104624-98-8 / antineoplaston AS 2-1; 91531-30-5 / antineoplaston A10
  •  go-up   go-down


50. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF: Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development; 2005 Dec;132(24):5577-88
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children with this disease suffer a high incidence of optic gliomas, a benign but potentially debilitating tumor of the optic nerve; and an increased incidence of malignant astrocytoma, reactive astrogliosis and intellectual deficits.
  • Primary among these is a developmental defect resulting in global reactive astrogliosis in the adult brain and increased proliferation of glial progenitor cells leading to enlarged optic nerves.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):361-7 [10931370.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7773-9 [15520182.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4450-9 [10442636.001]
  • [Cites] Neuron. 2000 May;26(2):533-41 [10839371.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Development. 2000 Dec;127(24):5253-63 [11076748.001]
  • [Cites] Neuron. 2000 Oct;28(1):69-80 [11086984.001]
  • [Cites] Nature. 2001 Feb 8;409(6821):714-20 [11217860.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] Nat Rev Neurosci. 2001 Apr;2(4):287-93 [11283751.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):885-90 [11294925.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Genesis. 2001 Oct;31(2):85-94 [11668683.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):112-7 [11689956.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5100-13 [12077339.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9228-36 [12417648.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):751-64 [12628166.001]
  • [Cites] J Neurosci. 2003 Aug 6;23(18):7207-17 [12904481.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8573-7 [14695164.001]
  • [Cites] Neuron. 2004 Mar 25;41(6):881-90 [15046721.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Cell. 1990 Nov 16;63(4):835-41 [2121369.001]
  • [Cites] Cell. 1990 Nov 16;63(4):851-9 [2121371.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] Dev Dyn. 1992 Nov;195(3):216-26 [1301085.001]
  • [Cites] Dev Biol. 1994 Feb;161(2):538-51 [8314000.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Development. 1994 Sep;120(9):2637-49 [7956838.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jul;54(4):588-600 [7602332.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] Development. 1995 Nov;121(11):3583-92 [8582272.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):862-72 [9001241.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] Brain Res. 1999 Jan 16;816(1):111-23 [9878702.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] J Neurosci. 1999 Feb 1;19(3):1049-61 [9920668.001]
  • (PMID = 16314489.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052606-01; United States / NINDS NIH HHS / NS / P50 NS052606; United States / NINDS NIH HHS / NS / P50 NS052606-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurofibromin 1
  • [Other-IDs] NLM/ NIHMS149022; NLM/ PMC2760350
  •  go-up   go-down


51. Huo L, Bi C, Fang J, Wang Y, Zhang M, Chen F: [Microsurgical treatment and prevention of postoperative complications for the fourth ventricle tumors in adults]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;34(7):642-5
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The extent of tumor removal should take into consideration the possible injury of brain stem respiratory center, especially tumors adherent to the brain stem.
  • CONCLUSION: Protecting the life center of brain stem and dredging the aqueduct outlet completely were the key to surgical success.
  • [MeSH-major] Astrocytoma / surgery. Cerebral Ventricle Neoplasms / surgery. Fourth Ventricle / surgery. Microsurgery / methods. Postoperative Complications / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Hydrocephalus / etiology. Hydrocephalus / prevention & control. Male. Middle Aged. Neurosurgical Procedures / methods. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648678.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


52. Rachinger W, Grau S, Holtmannspötter M, Herms J, Tonn JC, Kreth FW: Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only. J Neurol Neurosurg Psychiatry; 2009 Oct;80(10):1134-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only.
  • OBJECTIVE: The aim of the current prospective study was to analyse the validity of MRI based diagnosis of brainstem gliomas which was verified by stereotactic biopsy and follow-up evaluation as well as to assess prognostic factors and risk profile.
  • METHODS: Between 1998 and 2007, all consecutive adult patients with radiologically suspected brainstem glioma were included.
  • RESULTS: 46 adult patients were included.
  • Histological evaluation revealed pilocytic astrocytoma (n = 2), WHO grade II glioma (n = 14), malignant glioma (n = 12), metastasis (n = 7), lymphoma (n = 5), cavernoma (n = 1), inflammatory disease (n = 2) or no tumour/gliosis (n = 3).
  • In the subgroup with a verified brainstem glioma, negative predictors for length of survival were higher tumour grade (p = 0.002) and Karnofsky performance score < or =70 (p = 0.004).
  • CONCLUSION: Intra-axial brainstem lesions with a radiological pattern of glioma represent a very heterogeneous tumour group with completely different outcomes.
  • [MeSH-major] Biopsy / methods. Brain Stem Neoplasms / pathology. Glioma / pathology. Magnetic Resonance Imaging. Stereotaxic Techniques
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19520698.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Magrassi L, Conti L, Lanterna A, Zuccato C, Marchionni M, Cassini P, Arienta C, Cattaneo E: Shc3 affects human high-grade astrocytomas survival. Oncogene; 2005 Aug 4;24(33):5198-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies showed that in the embryo, Shc1 is maximally expressed in dividing CNS stem cells while it is silenced in mature neurons, where it is replaced by Shc3.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioblastoma / genetics. Glioblastoma / pathology. Neuropeptides / physiology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / biosynthesis. Adaptor Proteins, Signal Transducing / physiology. Adult. Apoptosis. Blotting, Western. Cell Differentiation. Cell Line. Cell Proliferation. Cell Survival. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Phosphorylation. Shc Signaling Adaptor Proteins. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870690.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Neuropeptides; 0 / SHC1 protein, human; 0 / SHC3 protein, human; 0 / Shc Signaling Adaptor Proteins
  •  go-up   go-down


54. Adam Y, Benezech J, Blanquet A, Fuentes JM, Bousigue JY, Debono B, Duplessis E, Espagno C, Plas JY, Lescure JP, Destandau J, Hladky JP, Grunewald P, Mahla K, Remond J, Louis E: [Intramedullary tumors. Results of a national investigation in private neurosurgery]. Neurochirurgie; 2010 Aug;56(4):344-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor removal was complete in the cases of ependymoma and hemangioblastoma and subtotal in the cases of astrocytoma.
  • Astrocytomas: 22 cases, with 14 cases of astrocytoma, two pilocytic astrocytoma, four malignant astrocytoma, and two glioblastoma.
  • [MeSH-major] Brain Stem Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Delayed Diagnosis. Female. Follow-Up Studies. France / epidemiology. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20097390.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


55. Wu-Chen WY, Jacobs DA, Volpe NJ, Dalmau JO, Moster ML: Intracranial malignancies occurring more than 20 years after radiation therapy for pituitary adenoma. J Neuroophthalmol; 2009 Dec;29(4):289-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The brainstem abnormality was presumptively diagnosed as a malignant glioma.
  • A 63-year-old man developed a malignant astrocytoma of the left optic nerve and chiasm 23 years after partial excision and radiation of a nonsecreting pituitary adenoma.
  • [MeSH-major] Adenoma / radiotherapy. Brain Stem Neoplasms / etiology. Glioma / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Optic Nerve Neoplasms / etiology. Pituitary Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Male. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952902.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Maekawa M, Fujisawa H, Iwayama Y, Tamase A, Toyota T, Osumi N, Yoshikawa T: Giant subependymoma developed in a patient with aniridia: analyses of PAX6 and tumor-relevant genes. Brain Pathol; 2010 Nov;20(6):1033-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Eye Proteins / genetics. Homeodomain Proteins / genetics. Paired Box Transcription Factors / genetics. Repressor Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aniridia / complications. Female. Humans

  • Genetic Alliance. consumer health - Aniridia.
  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors; Brain Pathology © 2010 International Society of Neuropathology.
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17306-13 [10747901.001]
  • [Cites] Stem Cells. 2009 Jan;27(1):40-8 [18948646.001]
  • [Cites] Tohoku J Exp Med. 2001 Mar;193(3):163-74 [11315763.001]
  • [Cites] Hum Genet. 2001 Jul;109(1):11-8 [11479730.001]
  • [Cites] Nucleic Acids Res. 2001 Oct 1;29(19):4070-8 [11574690.001]
  • [Cites] Schizophr Res. 2001 Dec 1;52(3):171-9 [11705711.001]
  • [Cites] Hum Mutat. 2003 Feb;21(2):138-45 [12552561.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Cancer. 1974 Dec;34(6):1992-2008 [4434329.001]
  • [Cites] Acta Neuropathol. 1977 Nov 28;40(3):279-82 [203160.001]
  • [Cites] J Neurosurg. 1978 Nov;49(5):689-96 [712391.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:6-16 [6953802.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):583-8 [1885976.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):463-71 [7951315.001]
  • [Cites] J Biol Chem. 1997 Feb 7;272(6):3430-6 [9013587.001]
  • [Cites] Dan Med Bull. 1997 Nov;44(5):535-9 [9408738.001]
  • [Cites] Int J Dev Biol. 2004;48(8-9):819-27 [15558474.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):223-9 [15735909.001]
  • [Cites] Neurosurgery. 2006 May;58(5):881-90; discussion 881-90 [16639322.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] J Neurosci. 2008 Apr 30;28(18):4604-12 [18448636.001]
  • [Cites] J Cell Biochem. 2008 Aug 15;104(6):2298-309 [18561328.001]
  • [Cites] Brain Pathol. 2008 Oct;18(4):469-73 [18397339.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1166-74 [18776908.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):179-85 [10861471.001]
  • (PMID = 20500513.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Eye Proteins; 0 / Homeodomain Proteins; 0 / PAX6 protein; 0 / Paired Box Transcription Factors; 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2991767
  •  go-up   go-down


57. Yen CP, Sheehan J, Steiner M, Patterson G, Steiner L: Gamma knife surgery for focal brainstem gliomas. J Neurosurg; 2007 Jan;106(1):8-17
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife surgery for focal brainstem gliomas.
  • OBJECT: Focal tumors, a distinct subgroup of which is composed of brainstem gliomas, may have an indolent clinical course.
  • In the present study the authors assess clinical and imaging results in 20 patients who harbored focal brainstem gliomas treated with GKS between 1990 and 2001.
  • In 10 cases a tumor specimen was obtained either by open surgery or stereotactic biopsy, securing the diagnosis of pilocytic astrocytoma in five patients and nonpilocytic astrocytoma in five others.
  • CONCLUSIONS: Gamma Knife surgery may be an effective primary treatment or adjunct to open surgery for focal brainstem gliomas.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Glioma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2007 Sep;107(3):708; author reply 708-9 [17886574.001]
  • [CommentIn] J Neurosurg. 2007 Jan;106(1):6-7 [17262931.001]
  • (PMID = 17236482.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Vital AL, Tabernero MD, Castrillo A, Rebelo O, Tão H, Gomes F, Nieto AB, Resende Oliveira C, Lopes MC, Orfao A: Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro Oncol; 2010 Sep;12(9):991-1003
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In summary, our results show a clear association between the GEP of gliomas and tumor histopathology; additionally, among grade IV astrocytoma, GEP are significantly associated with the cytogenetic profile of the ancestral tumor cell clone.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Gene Expression Profiling. Glioblastoma / genetics. Glioblastoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Cytogenetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biol Ther. 2003 May-Jun;2(3):242-7 [12878856.001]
  • [Cites] PLoS Med. 2009 Jan 13;6(1):e10 [19143470.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):316-25 [15507670.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):381-8 [9821169.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7820-6 [15585613.001]
  • [Cites] Cell. 2005 Mar 11;120(5):675-85 [15766530.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1087-98 [16731740.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17492-500 [16627485.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 15;351(2):336-9 [17067552.001]
  • [Cites] Int J Oncol. 2007 Jan;30(1):55-64 [17143512.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1181-8 [17146292.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):425-32 [10666371.001]
  • [Cites] Int J Oncol. 2001 Oct;19(4):673-80 [11562740.001]
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1229-36 [12479704.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Histol Histopathol. 2007 Mar;22(3):327-35 [17163407.001]
  • [Cites] Pathol Oncol Res. 2007;13(1):39-46 [17387387.001]
  • [Cites] Cell Mol Life Sci. 2007 Apr;64(7-8):796-802 [17364146.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1133-9 [17341657.001]
  • [Cites] Stem Cells. 2007 Jun;25(6):1498-506 [17322106.001]
  • [Cites] J Neurooncol. 2007 Oct;85(1):11-24 [17634744.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1225-36 [17962616.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7341-56 [18094416.001]
  • [Cites] J Neurooncol. 2008 Feb;86(3):297-309 [17928955.001]
  • [Cites] Am J Pathol. 2008 Jan;172(1):225-35 [18156210.001]
  • [Cites] Clin Transl Oncol. 2008 Feb;10(2):73-7 [18258505.001]
  • [Cites] Apoptosis. 2008 Mar;13(3):437-47 [18188704.001]
  • [Cites] Brain Res. 2008 Mar 27;1201:161-6 [18331723.001]
  • [Cites] Br J Cancer. 2008 Jun 3;98(11):1830-8 [18506188.001]
  • [Cites] Cell. 2009 Feb 6;136(3):473-84 [19203582.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2712-6 [19196966.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] J Biol Chem. 2008 Jun 13;283(24):16673-81 [18424444.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1368-73 [18559551.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] Mol Diagn Ther. 2008;12(4):199-208 [18652516.001]
  • [Cites] Ann Diagn Pathol. 2008 Oct;12(5):313-21 [18774492.001]
  • [Cites] J Immunol Methods. 2008 Nov 30;339(1):74-81 [18775433.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2955-60 [18770864.001]
  • [Cites] Neurogenetics. 2010 May;11(2):227-39 [19760258.001]
  • (PMID = 20484145.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940695
  •  go-up   go-down


59. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A: Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer; 2006 Jul;47(1):30-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types were: neuroblastoma (NB; n = 17), medulloblastoma (MB; 8), brain stem glioma (BSG; 8), extraosseous Ewing's sarcoma/peripheral neuroectodermal tumor (EOES; 4), Ewing's sarcoma (ES; 4), anaplastic astrocytoma (AA; 3), rhabdomyosarcoma (RMS; 2), ependymoma (EP; 2), cerebral primitive neuroectodermal tumor (cPNET; 2), hepatocarcinoma (HC; 1), and osteosarcoma (OS; 1).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2006 Oct 15;47(5):647-8
  • (PMID = 16047361.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


60. Beaty O 3rd, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, Voss S, Ivy SP, Adamson PC: A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2010 Sep;55(3):440-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologies included: Ewing sarcoma/peripheral PNET, osteosarcoma, rhabdomyosarcoma, neuroblastoma, high and low grade astrocytoma, brain stem glioma, ependymoma, hepatoblastoma and selected rare tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20658614.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10CA98413; United States / NCI NIH HHS / CA / U10CA98543; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  • [Other-IDs] NLM/ NIHMS218622; NLM/ PMC4665115
  •  go-up   go-down


61. Korones DN, Smith A, Foreman N, Bouffet E: Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr Blood Cancer; 2006 Jul;47(1):37-41
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnoses included recurrent brain stem glioma (2), recurrent anaplastic astrocytoma (2), and glioblastoma (7) (3 treatment-induced, 2 malignant transformations of lower grade tumors, 1 recurrence, and 1 second tumor arising 10 months after diagnosis of medulloblastoma).
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Child. Child, Preschool. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16047359.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


62. Yamada M, Tanaka H, Morita T, Takahashi H: Separate CNS lesions involving the brainstem and spinal cord in a 47-year-old man. Neuropathology; 2008 Jun;28(3):341-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Separate CNS lesions involving the brainstem and spinal cord in a 47-year-old man.
  • [MeSH-major] Astrocytoma / pathology. Brain Stem Neoplasms / pathology. Glioblastoma / pathology. Neoplasms, Multiple Primary / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Multiple Sclerosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021196.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


63. Redondo-Cerezo E, Viñuelas-Chicano M, Pérez-Vigara G, Gómez-Ruiz CJ, Sánchez-Manjavacas N, Jimeno-Ayllon C, Pérez-Sola A: A patient with persistent hiccups and gastro-oesophageal reflux disease. Gut; 2008 Jun;57(6):763, 771
MedlinePlus Health Information. consumer health - Hiccups.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / complications. Brain Stem Neoplasms / complications. Gastroesophageal Reflux / complications. Hiccup / etiology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477678.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement